Peter Sieger
Overview
Explore the profile of Peter Sieger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez-Fernandez K, Gomez-Mantilla J, Shukla S, Stopfer P, Sieger P, Mangas-Sanjuan V, et al.
Clin Pharmacokinet
. 2025 Feb;
PMID: 39899201
Introduction And Objective: Physiologically based pharmacokinetic (PBPK) models are increasingly used to predict food effect (FE) but model parameterization is challenged by in vitro-in vivo (IVIV) disconnect and/or parameter nonidentifiability....
2.
Block M, Sieger P, Truenkle C, Saal C, Simon R, Truebenbach I
Eur J Pharm Sci
. 2024 Feb;
196:106733.
PMID: 38408709
Microencapsulation of active pharmaceutical ingredients (APIs) for preparation of long acting injectable (LAI) formulations is an auspicious technique to enable preclinical characterization of a broad variety of APIs, ideally independent...
3.
Betzemeier B, Braun C, Sieger P, Heckel A, Linz G, Linehan B, et al.
Eur J Med Chem
. 2023 Dec;
265:116038.
PMID: 38157597
Lung selective inhibition of the endothelial sodium channel (ENaC) is a potential mutation agnostic treatment of Cystic Fibrosis (CF). We describe the discovery and development of BI 1265162, the first...
4.
Hermann M, Tautermann C, Sieger P, Grundl M, Weber A
Pharmaceuticals (Basel)
. 2023 Jan;
16(1).
PMID: 36678612
We present the first comprehensive study on the prediction of reactivity for propynamides. Covalent inhibitors like propynamides often show improved potency, selectivity, and unique pharmacologic properties compared to their non-covalent...
5.
Leino T, Sieger P, Yli-Kauhaluoma J, Wallen E, Kley J
Eur J Med Chem
. 2022 Apr;
237:114374.
PMID: 35436668
Azulene is a bicyclic scaffold rarely applied in medicinal chemistry. Here we report physicochemical and in vitro parameters relevant for drug discovery for a series of diversely substituted azulenes. We...
6.
Cui Y, Desevaux C, Truebenbach I, Sieger P, Klinder K, Long A, et al.
Pharmaceutics
. 2021 Aug;
13(8).
PMID: 34452112
Bidirectional permeability measurement with cellular models grown on Transwell inserts is widely used in pharmaceutical research since it not only provides information about the passive permeability of a drug, but...
7.
Gerlach K, Hobson S, Eickmeier C, Gross U, Braun C, Sieger P, et al.
Bioorg Med Chem
. 2018 May;
26(12):3227-3241.
PMID: 29735425
The identification and optimization of a novel series of centrally efficacious gamma secretase modulators (GSMs) offering an alternative to the privileged aryl imidazole motif is described. Chiral bicyclic tetrahydroindazolyl amine...
8.
Andersson S, Alvebratt C, Bevernage J, Bonneau D, Mathews C, Dattani R, et al.
J Pharm Sci
. 2016 Apr;
105(9):2864-2872.
PMID: 27112289
The purpose of this study was to investigate the interlaboratory variability in determination of apparent solubility (Sapp) and intrinsic dissolution rate (IDR) using a miniaturized dissolution instrument. Three poorly water-soluble...
9.
Heimink J, Sieger P, Koller H
J Pharm Sci
. 2011 May;
100(10):4401-12.
PMID: 21544821
The encapsulation of pharmaceutical drug molecules in silica gels during the sol-gel synthesis and their kinetic release profile in aqueous solutions were systematically investigated in dependence of synthesis pH(S) and...
10.
Casarosa P, Kollak I, Kiechle T, Ostermann A, Schnapp A, Kiesling R, et al.
J Pharmacol Exp Ther
. 2011 Mar;
337(3):600-9.
PMID: 21357659
β(2)-Adrenoceptor (β(2)-AR) agonists are powerful bronchodilators and play a pivotal role in the management of pulmonary obstructive diseases, such as asthma and chronic obstructive pulmonary disease. Although these agents first...